Abstract
The present study was designed to evaluate the local effects of the new mitomycin C analogue KW-2149 after intravesical instillation, together with its penetration into the systemic circulation in healthy beagle dogs. Two reference dogs were treated with two instillations of mitomycin C (30 mg in 30 ml phosphate buffer). Four dogs were given two, three, four and six instillations, respectively, of KW-2149 (60 mg in 30 ml phosphate buffer). KW-2149 concentrations measured in the systemic circulation were very low and were frequently found to be below the limit of determination. The number of instillations had no influence on the KW-2149 concentrations measured in the systemic circulation. Blood analysis showed no systemic toxicity. The histopathological findings in the bladder were comparable in both groups. The number of instillations had no influence on the severity of the lesions found in the bladder wall. On the basis of its in vitro activity KW-2149 can be regarded as a promising agent for intravesical treatment of superficial bladder cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bouffioux C, Denis L, Kurth KH, et al. (1988) Quelle chimiotherapie intravesicale pour quelle tumeur de vessie en 1988. J Urol 94:251
Denis L, Bouffioux C, Kurth KH, et al. (1987) Current status of intravesical chemotherapy trials in the EORTC Urological Group. An Overview. Cancer Chemother Pharmacol 20:67
Dirix L, Gheuens E, Van Der Heyden S, Van Oosterom AT, De Bruijn EA (1994) Cytotoxic activity of 7-N-(2-((2-(gamma-L-glutamylamino)ethyl)dithio)ethyl)mitomycin C and metabolites in cell lines with different resistance patterns. Anti-cancer Drugs 5:343
Friedman D, Mooppan UMM, Rosen Y, Kim H (1991) The effect of intravesical instillations of thiotepa, mitomycin C and adriamycin on normal urothelium: an experimental study in rats. J Urol 145:1060
Kono M, Saito Y, Kasai M, Sato A, Shirahata K, Morimoto M, Ashizawa T (1989) Synthesis and antitumor activity of 7-N-(2-((2-gamma-L-glutamylamino)ethyl)dithio)ethyl)mitomycin C. Chem Pharm Bull 37:1128
Kyowa Toxicological Research Laboratories (Toxicology Report on KW-2149) (1988) Kyowa Hakko Kogyo Co, Ltd., Suizuoka, Japan
Morimoto M, Ashizawa T, Ohno H, Azuma M, Kobayashi E, Okabe M, Gomi K, Kono M, Saitoh Y, Kanda Y, Arai H, Sato A, Kasai M, Tsuruo T (1991) Antitumor activity of 7-N-(2-((2-(gamma-L-glutamylamino)ethyl)dithio)ethyl)mitomycin C. Cancer Res 51:110
Pattyn G, Van Oosterom AT, De Bruijn EA, Tjaden UR (1991) Determination of the new anticancer agent KW-2149, 7-N-(2-((2-(gamma-L-glutamylamino)ethyl)dithio)ethyl) mitomycin C. J Chromatogr 564:352
Soloway MS (1990) Rationale for intensive intravesical chemotherapy for superficial bladder cancer. J Urol 123:461
Tjaden UR, Langenberg JP, Ensing K, Van Bennekom WP, De Bruijn EA, Van Oosterom AT (1982) Determination of mitomycin C in plasma, serum and urine by high-performance liquid chromatography with ultra-violet and electrochemical detection. J Chromatogr 232:355
Wientjes MG, Dalton JT, Badalement RA, Drago JR, Au JL (1991) Bladder wall penetration of intravesical mitomycin C in dogs. Cancer Res 51:4347
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sorber, M., De Bruijn, E.A., Kockx, M. et al. Effects and systemic uptake of the new mitomycin C analogue KW-2149 in beagle dogs after intravesical administration. Urol. Res. 23, 157–161 (1995). https://doi.org/10.1007/BF00389567
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00389567